A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL) Each Administered with a Background Regimen in HIV-1

Grants and Contracts Details

StatusFinished
Effective start/end date11/1/08 → 10/31/12

Funding

  • Gilead Sciences Inc: $6,590.00